[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632362":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":73,"collaborators":76,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":26,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":26,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Venetoclax Combined with CACAG Regimen","EXPERIMENTAL","Participants assigned to Venetoclax Combined with CACAG Regimen will receive a combination regimen consisting of venetoclax plus the CACAG. The CACAG regimen includes azacitidine administered at a dose of 75 mg\u002Fm² subcutaneously on days 1-7; cytarabine given at a dose of 75-100 mg\u002Fm² q12h intravenously on days 1-5; aclarubicin administered at a dose of 20 mg intravenously on days 1, 3, and 5; and chidamide given orally at a dose of 30 mg twice a week for two weeks. Venetoclax is administered orally with a dose ramp-up schedule: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3 through 14. If an azole antifungal agent is co-administered, the dose of venetoclax is reduced to 100 mg daily. Granulocyte colony-stimulating factor (G-CSF) is given subcutaneously at 300 μg per day until neutrophil recovery. Each treatment cycle lasts 4-5 weeks, with a total of 2 cycles.",[13],"Drug: CACAG+VEN",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard \"3+7\" Regimen","ACTIVE_COMPARATOR","Participants assigned toStandard \"3+7\" Regimen will receive the standard \"3+7\" induction regimen. Daunorubicin is administered intravenously at a dose of 60 mg\u002Fm² on days 1-3. Cytarabine is given intravenously at a dose of 75-100 mg\u002Fm² twice daily on days 1-7. Each treatment cycle lasts 4-5 weeks, with a total of 2 cycles. Participants who do not achieve at least a partial response after the first cycle will be withdrawn from the study and receive alternative treatment according to clinical guidelines.",[19],"Drug: 3+7",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","CACAG+VEN","Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor\n\n1. Azacytidine (75 mg\u002Fm2\u002Fday, days 1 to 7).\n2. Cytarabine (75-100 mg\u002Fm2 every 12 hrs, days 1 to 5).\n3. Aclacinomycin (20 mg\u002Fday, days 1,3,5).\n4. Chidamide (30 mg\u002Fday , days 1,4,8,11).\n5. Venetoclax is administered orally with a dose ramp-up schedule: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3 through 14. If an azole antifungal agent is co-administered, the dose of venetoclax is reduced to 100 mg daily. 6.Granulocyte colony-stimulating factor (G-CSF) is given subcutaneously at 300 μg per day until neutrophil recovery.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"3+7","IA regimen: 1. Idarubicin (8-10 mg\u002Fm2) for 3 days. 2.Cytarabine (75-100mg\u002Fm2, every 12 hrs) for 7 days.\n\nDA regimen: 1.Daunorubicin(60 mg\u002Fm2) for 3 days. 2.Cytarabine (75-100mg\u002Fm2, every 12 hrs) for 7 days.\n\nMA regimen: 1.Mitoxantrone (12 mg\u002Fm2) for 3 days. 2.Cytarabine (75-100mg\u002Fm2, every 12 hrs) for 7 days.",[15],[32],{"name":33,"affiliation":5,"role":34},"Liping Dou, Doctor","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+8613681207138","lipingruirui@163.com",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Daihong Liu, Doctor","+8613681171597","daihongrm@163.com",[45,59,66],{"facility":46,"status":47,"city":48,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Air Force Medical Center, PLA","RECRUITING","Beijing","China","CN",{"type":52,"coordinates":53},"Point",[54,55],116.39723,39.9075,{"lat":55,"lon":54},[58],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},{"facility":5,"status":47,"city":48,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},{"type":52,"coordinates":61},[54,55],{"lat":55,"lon":54},[64,65],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},{"facility":67,"status":47,"city":48,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},"PLA Strategic Support Force's Characteristic Medical Center",{"type":52,"coordinates":69},[54,55],{"lat":55,"lon":54},[72],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},{"type":34,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Liping Dou","Department Director",[77,80],{"name":78,"class":79},"Air Force Medical Center of PLA","UNKNOWN",{"name":67,"class":79},"100632362","phase-2-venetoclax-combined-with-cacag-regimen-versus-37-regimen-in-the-treatment-of-acute-monocytic-leukemia-100632362",false,"NCT07512700","Venetoclax Combined With CACAG Regimen Versus \"3+7\" Regimen in the Treatment of Acute Monocytic Leukemia","Venetoclax Combined With CACAG Regimen Versus \"3+7\" Regimen in the Treatment of Acute Monocytic Leukemia: A Prospective, Randomized, Controlled Study","Inclusion Criteria:\n\n* Voluntary participation with written informed consent signed by the participant or a legal guardian; willingness to comply with all study procedures.\n* Age 14 to 60 years at screening, no gender restriction.\n* Diagnosis of acute monocytic leukemia according to the 2016 WHO classification, excluding acute promyelocytic leukemia.\n* No history of severe allergic reactions.\n* Liver function: ALT and AST ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 2 × ULN.\n* Renal function: serum creatinine ≤ 1.5 × ULN\n* No uncontrolled infection or severe psychiatric disorder.\n* ECOG performance status 0-3; life expectancy ≥ 4 months.\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to any study drug.\n* Pregnancy or lactation.\n* Active infection.\n* Long-term smoking or alcohol abuse that may interfere with study outcome evaluation.\n* Psychiatric illness or other condition that prevents informed consent or compliance with study procedures.\n* Major organ surgery within 6 weeks prior to enrollment.\n* Abnormal liver function: total bilirubin \\> 2× ULN, ALT\u002FAST \\> 2.5 × ULN; abnormal renal function: serum creatinine \\> 1.5 × ULN.\n* Any condition deemed unsuitable for the study by the investigator (e.g., poor compliance, substance abuse).","ALL","14 Years","60 Years",{"count":92,"type":93},204,"ESTIMATED","INTERVENTIONAL",[96],"PHASE2","This study is a multicenter, randomized, prospective Phase II clinical trial designed to compare the effectiveness of two treatment approaches for patients with acute monocytic leukemia.",[99],"Acute Monocytic Leukemia",[99,101],"Venetoclax+CACAG","2026-04-02",{"date":104,"type":105},"2026-04-06","ACTUAL",{"date":107,"type":105},"2025-09-01",{"date":109,"type":93},"2029-10-31",{"name":5,"class":6},3]